Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patient Engagement for the Life Sciences

September 12, 2018 | Patient-centric, Patient-centricity, life sciences, patient engagement 

Patient Engagement for the Life Sciences, written by Guy Yeoman and Mitchell Silva with editorial and design support from Cuttsy+Cuttsy, explains the ‘why’ and the ‘how’ of patient engagement. It presents the compelling argument for why life science companies need to embrace and partner with patients and outlining an operating framework for doing it effectively.

Visit www.medipace.com/book to download your copy.

We’re really proud to have been working with Guy Yeoman and Mitch Silva on their new book, Patient Engagement for the Life Sciences. To celebrate the book launch, we’ve been talking to Guy about why patient engagement is so important to pharma. I’m a firm believer and I’m passionate about effective patient engagement. I think it delivers value for the industry, but also for patients and society at large. My background is in the pharmaceutical business. I’ve been working for the last two decades in the industry, and over the last three years I’ve built a patient-engaging capability for a large pharma organisation. So I come with that corporate, strategic background. The co-author of the book, Mitchell Silva, is a patient. He’s a patient expert himself, he’s a EUPATI scholar, and he’s built a virtual patient network for patients with cancer. So between us we bring both perspectives. We demonstrate clearly in the book why the industry needs to change, but also how it needs to change and what operating framework could be put in place that enables effective patient engagement, delivering value for both the industry as well as the patients and allied stakeholders.

This content was provided by Cuttsy + Cuttsy

Company Details

Cuttsy and Cuttsy Logo

Cuttsy + Cuttsy

Email
Website

 Latest Content from  Cuttsy + Cuttsy 

Caring for patients’ mental health in clinical trials

We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.

Driving equitable healthcare: The role of DE&I in clinical trials

Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and...

Empowering patients through more accessible clinical trial information

Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial...

New report now available: Integrating ‘patient first’ into medicine development

A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map...

The digital prescription – enhancing the patient experience with technology

We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.

Compliance — a driving force for influencing public perceptions of the pharma industry?

How does compliance play into public perceptions of pharma and why is it important for improving public opinion?

Another year, another B!

Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.

Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director

Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.

Clinical trial considerations: Why supporting HCPs matters…

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...